Scynexis

SCYX Rare disease Lead: Approved 3 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-04

Catalyst timeline

BREXAFEMME filing2026BREXAFEMME filing, 2026, notable
SCY-770 Ph2 readout3Q 2026SCY-770 Ph2 readout, 3Q 2026, material
SCY-247 Ph1 interim3Q 2026SCY-247 Ph1 interim, 3Q 2026, notable
SCY-770 Ph2 start4Q 2026SCY-770 Ph2 start, 4Q 2026, notable
SCY-770 Ph2 topline2H 2027SCY-770 Ph2 topline, 2H 2027, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

BREXAFEMME

ibrexafungerp

Small Molecule Target: glucan synthase

Vulvovaginal Candidiasis Approved oral GlaxoSmithKline NCT03059992

SCY-247

Small Molecule Target: glucan synthase

Invasive Candidiasis Phase 1 oral
Invasive Candidiasis Phase 1 intravenous
Invasive Fungal Infections Preclinical oral

SCY-770

Small Molecule Target: AMPK

Autosomal Dominant Polycystic Kidney Disease Phase 1 oral

Technology platforms

fungerps

Proprietary antifungal platform comprising a novel class of triterpenoid glucan synthase inhibitors with broad-spectrum activity against Candida, Aspergillus, Pneumocystis, Coccidioides, Histoplasma, Blastomyces genera and mucorales species, including multidrug-resistant strains; focus on difficult-to-treat and drug-resistant fungal infections.

Targets: glucan synthase

Biotech Distilled coverage (3)

2026-08-13 UPDATE: Scynexis (SCYX) - Adage Shows Up 🔒 Paid
2026-08-11 UPDATE: Scynexis (SCYX) - The Negative Enterprise Value Just Evaporated 🔒 Paid
2026-06-24 Scynexis, Inc. (SCYX) - Scientific Deep Dive for SCY-770 (ADPKD) and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.